Plain-English translation of NCT06636032 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing CellReady®, a treatment made from cells taken from fat tissue, to see if it can help heal fistulas (abnormal tunnels in the skin) that develop in people with Crohn's disease. The study will inject different amounts of these cells directly into the fistula to find the best dose. These fat-derived cells have natural healing and anti-inflammatory properties that may help repair damaged tissue.
Many people with Crohn's disease develop painful fistulas that do not heal with standard treatments like drainage tubes and anti-inflammatory medications. This trial is exploring whether this medication might offer a new option for patients whose fistulas have not responded to conventional care.
You likely qualify if…
You likely don't qualify if…
You will come to the hospital for an injection procedure where cells are injected into your fistula wall. The study will test two different doses to see which works best, with small groups of patients receiving each dose. You will have follow-up visits to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
France